Serum osteocalcin concentrations in patients with multiple myeloma — correlation with disease stage and survival
- 1 February 1992
- journal article
- Published by Wiley in Journal of Internal Medicine
- Vol. 231 (2) , 133-137
- https://doi.org/10.1111/j.1365-2796.1992.tb00514.x
Abstract
Multiple myeloma affects bone, and enhanced bone resorption is a characteristic finding. In the present study the serum concentration of osteocalcin, serum bone gla-protein, which is a protein specific for bone turnover and reflects osteoblast activity, was analysed at diagnosis in 48 patients with multiple myeloma. At that time there was a significant relationship between disease stage (Durie-Salmon) and osteocalcin levels, lower levels being found in patients with more advanced disease. No relationship was found between osteocalcin and serum calcium levels. To date, 33 patients have died. There was a significant correlation between initial osteocalcin levels and patient survival. These findings suggest that serum osteocalcin could be a marker of prognostic significance for survival in multiple myeloma.Keywords
This publication has 23 references indexed in Scilit:
- The role of interleukin‐1 and tumour necrosis factor‐α in human multiple myelomaBritish Journal of Haematology, 1990
- Spontaneous secretion of tumor necrosis factor-beta by human myeloma cell linesCancer, 1989
- OsteocalcinClinical Orthopaedics and Related Research, 1988
- Prognostic value of serum lactic dehydrogenase (S‐LDH) in multiple myelomaEuropean Journal of Clinical Investigation, 1987
- Serum osteocalcin in rheumatoid arthritis and other inflammatory arthritides: relation between inflammatory activity and the effect of glucocorticoids and remission inducing drugs.Annals of the Rheumatic Diseases, 1986
- Pretreatment serum β2‐microglobulin in multiple myelomaBritish Journal of Haematology, 1986
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- Serum beta2microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.British Journal of Haematology, 1983
- Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myelomaEuropean Journal of Cancer and Clinical Oncology, 1983
- Quantitative histology of myeloma‐induced bone changesBritish Journal of Haematology, 1982